Exploiting the MIBG-avidity of neuroblastoma for staging and treatment

Pediatric Blood and Cancer

Volumn 47, Issue 7, 2006, Pages 863-864

  Kushner, Brian H ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; MEDRONATE TECHNETIUM TC 99M;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SCINTISCANNING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INTERNATIONAL COOPERATION; INTERNATIONAL NEUROBLASTOMA RESPONSE CRITERIA; MEDICAL SOCIETY; NEUROBLASTOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

3-IODOBENZYLGUANIDINE; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; RADIOPHARMACEUTICALS;

EID: 33750454805     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20821     Document Type: Short Survey

References (15)

1. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993;11:1466-1477.
2. Bonnin F, Lumbroso J, Tenenbaum F, et al. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-810.
3. Ruffini V, Fisher GA, Shulkin BL, et al. Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464-1468.
4. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004;22:3909-3915.
5. 123I-MIBG whole body scan scoring method - Application to the prediction of the response of metastases to induction chemotherapy of stage IV neuroblastoma. Eur J Cancer 1995;1A:256-261.
6. Sue A, Lumbroso J, Rubie H, et al. Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77:805-811.
7. Perel Y, Conway J, Kletzel M, et al. Clinical impact and prognostic value of metaiodo-benzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol/Oncol 1999;21:13-18.
8. Frappaz D, Bonneu A, Chauvot P, et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation. Med Pediatr Oncol 2000;34:237-241.
9. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-2491.
10. Kushner BH, Yeh SDJ, Kramer K, et al. Impact of MIBG scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082-1086.
11. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005;44:232-239.
12. 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998;34:1398-1402.
13. Mastrangelo S, Tornesello A, Diociaiuti L, et al. Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 2001;84:460-464.
14. 131I]meta-iodobezylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 2005;11:7929-7937.
15. Matthay KK, Tan JC, Villablanca JG, et al. Phase 1 dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study. J Clin Oncol 2006;24:500-506.